 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Incara Pharmaceuticals Corporation
 |
Incara Pharmaceuticals Corporation |
 |
 |
 |
PROFILE |
 |
Development-stage Incara Pharmaceuticals is in search of the right drug for the right disease. The company is developing a treatment for inflammatory bowel disease; the drug, which is being developed in collaboration with Elan, is in clinical trials. Subsidiary Aeolus Pharmaceuticals is developing treatments for heart attack and stroke using catalytic antioxidant drugs; such drugs may also be used to treat respiratory ailments and arthritis. Incara's Renaissance Cell Technologies conducts research on liver progenitor cell therapy for treatment of liver failure. The company has research agreements with such institutions as Duke University, the University of North Carolina, and the Albert Einstein College of Medicine.
COMPETITION |
 |
Centocor, Inc. (dossier)
Rigel Pharmaceuticals, Inc. (RIGL)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: September
2000 Sales (mil.): 0.10
1-Yr. Sales Growth: (95.2)%
Employees: 21
Revenue per employee: $4,761.90
KEY PEOPLE |
 |
Clayton I. Duncan
CEO
Richard W. Reichow
CFO
CONTACT INFO |
 |
3200 E. Hwy. 54, Cape Fear Bldg., Ste. 300
Research Triangle Park, NC 27709
US
Phone: 919-558-8688
Fax: 919-558-8686
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |